Meropenem Pediatric Dose — Antimicrobial Reference
Meropenem is a broad-spectrum carbapenem beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins (PBPs). It demonstrates activity against a wide range of gram-positive, gram-negative, and anaerobic organisms, including many extended-spectrum beta-lactamase (ESBL)-producing pathogens. In pediatrics, it is used for serious and complicated infections including intra-abdominal infections, meningitis, febrile neutropenia, and nosocomial or multidrug-resistant infections in the PICU setting.
Pediatric Dosing
- Standard dose: 20 mg/kg/dose IV every 8 hours
- Adult dose (maximum reference): 1 g/dose IV every 8 hours
Doses should not routinely exceed the adult dose of 1 g/dose every 8 hours. Consult institutional protocol for higher doses used in CNS infections or based on organism susceptibility and pharmacokinetic/pharmacodynamic targets.
Worked example: For a 20 kg child: 20 kg × 20 mg/kg = 400 mg IV every 8 hours. For a 60 kg adolescent, the adult cap applies: 1 g IV every 8 hours.
Indications and Clinical Context
Meropenem is indicated for serious bacterial infections where broad-spectrum or carbapenem-level coverage is clinically warranted. Common indications include complicated intra-abdominal infections, bacterial meningitis, complicated urinary tract infections, hospital-acquired and ventilator-associated pneumonia, febrile neutropenia in immunocompromised patients, and infections caused by confirmed or suspected multidrug-resistant gram-negative organisms. It is frequently employed in the PICU as empiric or definitive therapy when narrower-spectrum agents are insufficient or culture and sensitivity data support its use.
Carbapenem stewardship should guide prescribing decisions. De-escalation to a narrower-spectrum agent is recommended once culture and sensitivity results are available, consistent with standard antimicrobial stewardship principles.
Administration and Monitoring
Meropenem is administered intravenously. It may be given as an IV bolus (over 15–30 minutes) or as an extended infusion (over 3–4 hours) depending on institutional protocol and pharmacodynamic optimization goals for resistant organisms. Ensure adequate IV or IO access; IO route may be used in emergent situations. Dose adjustment is required in renal impairment — consult institutional protocol or pharmacy for weight-based renal dosing guidance.
- Monitor: Renal function (SCr, BUN), hepatic enzymes, CBC for prolonged courses
- Adverse effects: Diarrhea, nausea, elevated transaminases, injection site reactions; seizures reported rarely, particularly at high doses or in patients with CNS pathology or renal impairment
- Contraindications: Known hypersensitivity to meropenem or other carbapenems; use with caution in patients with serious penicillin allergy — consult allergy/immunology or pharmacy
- Max single dose: 1 g/dose per the adult reference dose; consult institutional protocol for CNS-directed dosing
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.